Clinical trials: Chronic Leukaemia
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma.
- Conditions
- Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma
- Trial name
- NCT05512390
- Testing
- ABBV-319
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
The purpose of this study is to assess the benefit of lonafarnib (versus placebo) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Myelodysplasia, Myelomonocytic
- Trial name
- NCT00109538
- Testing
- Lonafarnib
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Chronic Lymphocytic Leukemia
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02970318
- Testing
- Acalabrutinib (ACP-196), Rituximab, Idelalisib
- Where
- 157 sites in United States, Australia and 23 more
- Volunteers
- 310 people
- Sponsor
- Acerta Pharma BV
Acute Leukemia, Chronic Leukemia
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
Genzyme will evaluate/monitor the off label transplant use of plerixafor using data in the European Group for Blood and Marrow Transplantation (EBMT) registry.
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT01362985
- Volunteers
- 201 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is a multi-center, open-label, dose escalation study.
- Trial name
- NCT01699152
- Testing
- TG02 citrate
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL
This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL.
- Trial name
- NCT01203930
- Testing
- Idelalisib, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 105 people
- Sponsor
- Gilead Sciences
Chronic Myeloid Leukemia
TGRX-678 Phase I Oral Pharmacokinetic Study
A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678
- Trial name
- NCT06697899
- Testing
- TGRX-678
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Trial name
- NCT06973187
- Testing
- Tacabrutideg, Pirtobrutinib
- Where
- 217 sites in United States, Argentina and 22 more
- Volunteers
- 500 people
- Sponsor
- BeOne Medicines
Hematological Malignancies
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the…
- Trial name
- NCT01607892
- Testing
- KPT-330
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Karyopharm Therapeutics Inc
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.
- Trial name
- NCT05147467
- Testing
- APG2575
- Where
- 11 sites in China
- Volunteers
- 75 people
- Sponsor
- Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia (CLL)
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
This study is to provide idelalisib (IDELA) to individuals with relapsed, previously treated chronic lymphocytic leukemia (CLL) who have limited treatment options and are not eligible for other Gilead-sponsored studies.
- Trial name
- NCT02136511
- Testing
- Idelalisib, Rituximab
- Where
- 8 sites in United States, Ireland and 2 more
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma
To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.
- Trial name
- MDX1411-02 (NCT00730652)
- Testing
- MDX-1411
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
B-cell Chronic Lymphocytic Leukemia
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL
This phase I/II study is designed to determine the safety and tolerability of APO866 for the treatment of refractory B-CLL not amenable to aHSCT.
- Trial name
- NCT00435084
- Testing
- APO866
- Where
- 4 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Valerio Therapeutics
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Trial name
- ALPINE (NCT03734016)
- Testing
- Zanubrutinib, Ibrutinib
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 652 people
- Sponsor
- BeiGene
Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal…
- Trial name
- MACS0911 (NCT01043874)
- Testing
- Nilotinib
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
CLL/SLL
A Study to Evaluate ICP-022 in Patients With CLL/ SLL
The phase I/II clinical study is to investigate the safety, tolerability and efficacy of ICP-022 in R/R CLL/SLL patients.
- Trial name
- NCT03493217
- Testing
- ICP-022
- Where
- 25 sites in China
- Volunteers
- 100 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with relapsed/ refractory B-cell Non-Hodgkin…
- Trial name
- NCT04540796
- Testing
- JNJ-75348780
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 147 people
- Sponsor
- Janssen Research & Development, LLC